At a time when many Americans are clamoring for more transparency into prescription drug pricing, one key provider of that data is making it harder to access the information.
A new venture called Merative — which was formed recently from the ashes of IBM’s Watson Health division — has decided it will no longer provide the media with pricing changes for specific medicines. This includes details such as separate doses and packaging on both current and historical prices.